I interview Dr. Birhiray who asked a critical & provocative question at yesterday’s ⁦ASH⁩ #ASH21 session. Why allow an abstract at a plenary if enrollees at the study presented do NOT represent US demographics? Hear proposed solutions. #HealthcareUnfiltered

Frustrated by this lack of inclusion, Dr. Ruemu Birhiray & maya nicole birhiray developed a strategy to increase inclusion in clinical trials: DRIVE. They hope to make DRIVE an industry standard & continue to advocate for #HealthEquity 👏🏻👏🏼👏🏾👏🏿 Read more: loom.ly/zPYrXPs (3/3)

I have been deeply moved this past week by how many others have reached out to me to share their own personal stories of struggle - and how much my willingness to do so means to them. I am so deeply honored 🙏🏻 youtu.be/p9ytQa_hW70 #culturechange #healthcare

On the 👠 of ASCO’s ESR1 rec, we 🗣 #Elacestrant and how it fits in our daily practice for HR+ #breastcancer with VIRGINIA KAKLAMANI Full Int: - targetedonc.com/pivotal-practi… - oncbrothers.com/emerald-journa… - Also on the “Oncology Brothers” podcast #bcsm #OncTwitter #MedTwitter Targeted Oncology

Cancer drug shortage causes risk of patients running out of medicine as doctors work to 'squeeze out the last bit of these drugs' Julie Gralow joins Natasha Raquel Kirtchuk to break down how the closure of one plant in India

Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median PFS of 8.61 months with elacestrant compared with 1.91 months for those given SOC #oncology #nursing #bcsm #ASCO23 ow.ly/3cUS50OOBbj

The new guidelines indicate that blood-based ctDNA testing is preferred due to greater sensitivity. Guardant360® CDx test is the only FDA-approved CDx to identify patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant). bit.ly/3Jm8r5l

Amazing weekend in Kona at the 1st annual #DAVAHawaiiBreast 🌸 Summit hosted by DAVA Oncology. Superstar faculty 🤩 and gorgeous setting. Proud to be part of the Menarini Stemline US Regional Marketing Team Susan Bergen @mollyhollman3 Jennifer Whipkey Julia Bolduc

Discover a treatment option for metastatic breast cancer. Watch the on-demand broadcast to learn about when and how to test for an ESR1 mutation. bit.ly/3QVOczU

🛎️ Our latest "Ask the Expert" webinar is happening soon! Learn about ESR1 mutations from Dr. Anne O’Dea, Medical Director of Breast Cancer Survivorship and Breast Cancer Clinical Research Program Services University of Kansas Medical Center: bit.ly/3sHSEZ7

.@eu_commission Approves Elacestrant for Pretreated, ESR1+, ER+/HER2– Breast Cancer G Curigliano MD PhD #bcsm bit.ly/3PLBS4f

Sheila Johnson, living with #metastaticbreastcancer for 13 years, veteran, and clinical trial participant advocates for #clinicaltrials becoming standard of care and we all "get online, get involved, research, ask questions." youtu.be/IKcxdEe2FqE #bcam

A hauntingly beautiful essay. Also a testament to how deeply oncology pharmacists are committed to improving the lives of patients ❤️

Thrilled to represent Menarini Stemline at my 9th SABCS and favorite meeting to date!